脂质负荷与易损冠状动脉斑块预防性PCI疗效:PREVENT试验事后分析
该研究为PREVENT随机对照试验的事后分析,纳入598例患者共632处斑块,基于近红外光谱衍生的脂质核心负荷指数(LCBI)定义脂质丰富斑块(LRP,4 mm段最大LCBI>315)。中位随访5.6年显示,LRP患者主要复合终点事件发生率高于非LRP患者(12.5% vs 4.7%);在LRP组中预防性PCI较单纯最佳药物治疗显著降低主要终点风险(7.3% vs 17.6%,校正HR 0.23,95%CI 0.13-0.41,P<0.001),非LRP组未见获益,治疗策略与LRP存在显著交互作用(P交互<0.001)。
要点
- 近红外光谱定义的脂质丰富斑块(4 mm段最大LCBI>315)患者主要复合终点事件风险更高。
- 脂质丰富斑块患者接受预防性PCI较单纯最佳药物治疗主要终点风险显著降低。
- 非脂质丰富斑块患者预防性PCI未见获益,治疗策略与LRP存在显著交互作用。
核心结论
- 在PREVENT试验事后分析中,预防性PCI与近红外光谱定义脂质丰富斑块患者主要复合终点风险降低相关。
- 非脂质丰富斑块患者尽管斑块负荷大且最小管腔面积小,预防性PCI未见显著获益。
- 斑块成分可能比单纯形态学严重程度更重要地指导预防性PCI决策。
研究设计与样本
- PREVENT试验(2015年9月至2021年9月)为研究者发起、多中心、开放标签、随机对照试验,共纳入1606例患者。
- 本事后分析纳入598例患者(平均年龄64.1±8.8岁,女性27.9%)共632处斑块,均经血管内超声确认斑块负荷>70%且最小管腔面积<4 mm²并接受近红外光谱评估。
主要发现
- 脂质丰富斑块见于223例患者(37.3%)共234处病变。
- 中位随访5.6年,总体人群中LRP患者主要终点事件发生率高于非LRP患者(12.5% vs 4.7%;未校正HR 2.08,95%CI 1.03-4.19,P=0.039)。
- LRP组中预防性PCI较单纯最佳药物治疗主要终点风险更低(7.3% vs 17.6%;校正HR 0.23,95%CI 0.13-0.41,P<0.001)。
- 非LRP组中预防性PCI未见获益(5.5% vs 4.2%;校正HR 1.00,95%CI 0.54-1.86,P=0.97)。
- 治疗策略与LRP存在显著交互作用(P交互<0.001)。
关键数值与推荐
- 脂质丰富斑块预设定义为4 mm段最大脂质核心负荷指数>315。
- 主要终点为心源性死亡、靶血管心肌梗死、缺血驱动靶血管血运重建或不稳定/进展性心绞痛住院的复合终点。
临床怎么用
- 对于近红外光谱评估显示脂质丰富斑块(4 mm段最大LCBI>315)的非血流限制性高危病变,预防性PCI可能降低主要复合终点风险。
- 对于非脂质丰富斑块,即使斑块负荷>70%且最小管腔面积<4 mm²,预防性PCI未见获益,应避免仅依据形态学严重程度进行干预。
局限性
- 本分析为PREVENT试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preventive percutaneous coronary intervention (PCI) of non-flow-limiting lesions (fractional flow reserve >0.80) that are high-risk plaques has emerged as a potential strategy to reduce cardiac events. However, identifying which lesions derive the greatest benefit from preventive PCI compared with optimal medical therapy alone remains challenging. This post hoc analysis evaluates the role of the near-infrared spectroscopy-derived lipid core burden index in identifying high-risk plaques that may benefit from preventive PCI. METHODS: Among the 1606 patients enrolled in the PREVENT trial (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) from September 2015 to September 2021, an investigator-initiated, multicenter, open-label, randomized controlled trial, this post hoc analysis included 598 patients (mean age, 64.1±8.8 years; 27.9% women) comprising 632 lesions with a plaque burden >70% and a minimal lumen area <4 mm2 by intravascular ultrasound in whom near-infrared spectroscopy evaluation was also performed. Lipid-rich plaque (LRP) was prespecified as having a maximum lipid core burden index over a 4-mm segment >315. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina. RESULTS: LRPs were present in 223 patients (37.3%) with 234 lesions. During median follow-up of 5.6 years, primary outcome events occurred more frequently in patients with LRPs than in those with non-LRPs (12.5% versus 4.7%; unadjusted hazard ratio, 2.08; 95% CI, 1.03-4.19; P=0.039) in the overall population. Within the LRP group, preventive PCI was associated with a lower risk of the primary outcome compared with optimal medical therapy alone (7.3% vs. 17.6%; adjusted hazard ratio, 0.23; 95% CI, 0.13-0.41; P<0.001). Conversely, no benefit of preventive PCI was observed in the non-LRP group (5.5% versus 4.2%; adjusted hazard ratio, 1.00; 95% CI, 0.54-1.86; P=0.97). A significant interaction was found between treatment strategy and the presence of LRP (Pinteraction<0.001). CONCLUSIONS: In this post hoc analysis of the PREVENT trial, preventive PCI was associated with a lower risk of the primary composite outcome in patients with near-infrared spectroscopy-defined LRPs, whereas no significant association was observed in those with non-LRPs despite their large plaque burden and small minimal lumen area. These findings suggest the importance of plaque composition, beyond morphological severity alone, in guiding preventive PCI. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02316886.
引用
- Wee SB, Ahn JM, Kang DY, et al. Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial. Circulation. 2026. PMID: 42836296. doi:10.1161/CIRCULATIONAHA.126.080384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。